- Everything Genetic Ltd has been granted the sole UK distribution rights for Caris Life Sciences’ MI Tumor Seek, a comprehensive molecular profiling service used to help guide the management of advanced cancer.
Everything Genetic Ltd, a UK based organisation offering genetic testing services for the diagnosis, prevention and treatment of a range of conditions, including cancer, has been granted the sole UK distribution rights for Caris Life Sciences (Caris)’ MI Tumor Seek service. The leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, Caris’ suite of market-leading tissue based molecular profiling offerings assess DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients.
The partnership complements Everything Genetic’s existing portfolio of cancer risk testing, which enable individuals to make informed decisions about their health and to take preventative measures that include regular screening programmes and improved lifestyle choices.
Headquartered in the U.S., Caris has built the world’s largest and most informative platform for analysing cancers with the most advanced and comprehensive tumor profiling available (Whole Exome and Whole Transcriptome Sequencing) across all 22,000 genes. Their MI Tumor Seek molecular profiling assay provides oncologists and surgeons with clinically important genomic information on key biomarkers and molecular signatures in oncology across all solid tumours.
James Price, Chief Executive Officer at Everything Genetic, said: “We are delighted to partner with Caris Life Sciences for the sole UK distribution of MI Tumor Seek, their comprehensive molecular profiling service. The partnership will enable medical teams across the UK to access the precision diagnostic technologies for biomarker identification, and therefore to fully understand the biology of a tumour and to implement the best treatment strategy for their cancer patients. The partnership strengthens Everything Genetic’s position as the partner of choice for genetic testing in the UK.”
Andreas Tsukada, SVP and Head of International at Caris Life Sciences, said: “We are pleased to partner with Everything Genetic for the distribution of MI Tumor Seek in the UK, further supporting Caris’ goal of improving the lives of as many people as possible. This collaboration provides healthcare professionals the access to best-in-class diagnostic technologies that will enable them to make more precise and individualised treatment decisions for their cancer patients.”
Everything Genetic will leverage its pedigree as a Sunday Times Top 100 fastest growing UK business to expand existing partnerships with healthcare providers, and to build new ones, ensuring better access to genetic testing and enabling them to provide the highest standard of care for patients.
